CN1327897C - Hiv感染的肽衍生物融合抑制剂 - Google Patents

Hiv感染的肽衍生物融合抑制剂 Download PDF

Info

Publication number
CN1327897C
CN1327897C CNB038164345A CN03816434A CN1327897C CN 1327897 C CN1327897 C CN 1327897C CN B038164345 A CNB038164345 A CN B038164345A CN 03816434 A CN03816434 A CN 03816434A CN 1327897 C CN1327897 C CN 1327897C
Authority
CN
China
Prior art keywords
peptide
fmoc
seq
glu
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB038164345A
Other languages
English (en)
Chinese (zh)
Other versions
CN1668330A (zh
Inventor
谢东
姜和
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Frontier Biopharmaceutical Nanjing Ltd By Share Ltd
Original Assignee
Frontier Biotechnologies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frontier Biotechnologies Co Ltd filed Critical Frontier Biotechnologies Co Ltd
Publication of CN1668330A publication Critical patent/CN1668330A/zh
Application granted granted Critical
Publication of CN1327897C publication Critical patent/CN1327897C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038164345A 2002-09-24 2003-09-23 Hiv感染的肽衍生物融合抑制剂 Expired - Lifetime CN1327897C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41279702P 2002-09-24 2002-09-24
US60/412,797 2002-09-24

Publications (2)

Publication Number Publication Date
CN1668330A CN1668330A (zh) 2005-09-14
CN1327897C true CN1327897C (zh) 2007-07-25

Family

ID=32043189

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038164345A Expired - Lifetime CN1327897C (zh) 2002-09-24 2003-09-23 Hiv感染的肽衍生物融合抑制剂

Country Status (15)

Country Link
US (3) US7575750B2 (https=)
EP (1) EP1542718B1 (https=)
JP (2) JP5385497B2 (https=)
CN (1) CN1327897C (https=)
AP (1) AP2203A (https=)
AU (2) AU2003275116A1 (https=)
BR (1) BR0314657A (https=)
CA (1) CA2500248C (https=)
CR (1) CR7806A (https=)
EA (1) EA007918B1 (https=)
ES (1) ES2558680T3 (https=)
IL (1) IL167527A (https=)
NZ (1) NZ539539A (https=)
WO (1) WO2004029201A2 (https=)
ZA (1) ZA200503118B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE295370T1 (de) 2001-05-31 2005-05-15 Conjuchem Inc Langwirkende fusionspeptid-inhibitoren für hiv- infektion
EP1542718B1 (en) * 2002-09-24 2015-11-11 Dong Xie Peptide derivative fusion inhibitors of hiv infection
CN100455594C (zh) * 2005-12-14 2009-01-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
CN1793170A (zh) * 2005-12-14 2006-06-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
CN101384623B (zh) * 2005-12-22 2013-07-24 常山凯捷健生物药物研发（河北）有限公司 白蛋白与治疗剂的预成型偶联物的制备方法
WO2008144590A2 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Long lasting modified antifusogenic peptide for preventing hiv infection
WO2012022040A1 (zh) * 2010-08-19 2012-02-23 清华大学 Hiv-1病毒膜融合抑制剂及其应用
CN103664701A (zh) * 2013-11-29 2014-03-26 成都普康生物科技有限公司 [2-[2-(Fmoc-氨基)乙氧基]乙氧基]乙酸合成路线
WO2020223906A1 (en) 2019-05-07 2020-11-12 Frontier Biotechnologies Inc. Stable albuvirtide compositions
WO2022003674A1 (en) * 2020-06-28 2022-01-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Neutrophil-binding peptides
CN115025218B (zh) * 2021-07-30 2025-03-28 前沿生物药业(南京)股份有限公司 联用治疗人类免疫缺陷病毒的活性组合及其应用
WO2024238349A1 (en) * 2023-05-12 2024-11-21 Frontier Medicines Corporation Identification and characterization of protein sites

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069911A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
WO2000070665A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting anti-angiogenic peptides
CN1339318A (zh) * 2000-08-18 2002-03-13 清华大学 一种治疗艾滋病的药物及其制备方法
CN1351611A (zh) * 1999-05-17 2002-05-29 康久化学公司 病毒感染的长效融合肽抑制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) * 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US3791667A (en) * 1972-05-04 1974-02-12 H Haviland Retractable vehicle passenger cushioning system
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
AU666853B2 (en) 1991-04-05 1996-02-29 Genentech Inc. Platelet aggregation inhibitors having high specificity for GP IIbIIIa
AU723537B2 (en) * 1995-06-07 2000-08-31 Trimeris Inc. The treatment of HIV and other viral infections using combinatorial therapy
US5624902A (en) 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
US6268479B1 (en) 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
CA2373680C (en) * 1999-05-17 2008-07-29 Conjuchem Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6750008B1 (en) * 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
EP1542718B1 (en) * 2002-09-24 2015-11-11 Dong Xie Peptide derivative fusion inhibitors of hiv infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069911A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
WO2000070665A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting anti-angiogenic peptides
CN1351611A (zh) * 1999-05-17 2002-05-29 康久化学公司 病毒感染的长效融合肽抑制剂
CN1339318A (zh) * 2000-08-18 2002-03-13 清华大学 一种治疗艾滋病的药物及其制备方法

Also Published As

Publication number Publication date
CA2500248A1 (en) 2004-04-08
ZA200503118B (en) 2006-11-29
JP2006505536A (ja) 2006-02-16
JP2010209097A (ja) 2010-09-24
WO2004029201A3 (en) 2004-08-12
CN1668330A (zh) 2005-09-14
AU2010200823B2 (en) 2011-12-15
US20110003735A1 (en) 2011-01-06
AU2010200823A1 (en) 2010-03-25
US8470527B2 (en) 2013-06-25
AU2003275116A1 (en) 2004-04-19
EP1542718B1 (en) 2015-11-11
EA007918B1 (ru) 2007-02-27
JP5385497B2 (ja) 2014-01-08
AP2203A (en) 2011-01-31
NZ539539A (en) 2006-11-30
CR7806A (es) 2007-09-07
WO2004029201A2 (en) 2004-04-08
IL167527A (en) 2013-12-31
BR0314657A (pt) 2005-08-02
US20050089840A1 (en) 2005-04-28
US20140187476A1 (en) 2014-07-03
ES2558680T3 (es) 2016-02-08
US7575750B2 (en) 2009-08-18
EP1542718A2 (en) 2005-06-22
AP2005003291A0 (en) 2005-06-30
CA2500248C (en) 2013-03-19
EP1542718A4 (en) 2011-04-06
EA200500533A1 (ru) 2005-12-29

Similar Documents

Publication Publication Date Title
US8470527B2 (en) Method of inhibiting HIV-1 replication by administering modified GP41 C34 peptide derivatives with enhanced pharmacological properties
EP1390399B1 (en) Long lasting fusion peptide inhibitors for hiv infection
US20090088377A1 (en) Cysteic acid derivatives of anti-viral peptides
CN100455594C (zh) 抑制hiv病毒融合的多肽及其用途
US20090088378A1 (en) Long lasting inhibitors of viral infection
EP1479691B1 (en) Long lasting fusion peptide inhibitors for HIV infection
US20080312415A1 (en) Long lasting fusion peptide inhibitors for hiv infection
WO2007068163A1 (en) Hiv fusion inhibitor peptides and use thereof
EP1752469B1 (en) Long lasting fusion peptide inhibitors for HIV infection
HK1071379B (en) Long lasting fusion peptide inhibitors for hiv infection
HK1099560A (en) Long lasting fusion peptide inhibitors for hiv infection
HK1125948A (en) Long lasting fusion peptide inhibitors of viral infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: CHONGQING SHENGSHENG HONGKUN ENTERPRISE MANAGEMENT

Free format text: FORMER OWNER: FRONTIER BIOTECHNOLOGIES CO. LT

Effective date: 20130624

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 400041 JIULONGPO, CHONGQING TO: 401120 YUBEI, CHONGQING

TR01 Transfer of patent right

Effective date of registration: 20130624

Address after: 401120 Chongqing city Yubei District back street four Xingke Road No. 149 Metro villa 13 buildings 1-9

Patentee after: Chongqing Sheng Sheng Hongkun Enterprise Management Consulting Co.,Ltd.

Address before: 400041, I, 3rd floor, four street, 70 Garden Street, Chongqing hi tech Zone

Patentee before: FRONTIER BIOTECHNOLOGIES Co.,Ltd.

ASS Succession or assignment of patent right

Owner name: NANJING FRONTIER BIOTECHNOLOGIES CO., LTD.

Free format text: FORMER OWNER: CHONGQING SHENGSHENG HONGKUN ENTERPRISE MANAGEMENT CONSULTANT CO., LTD.

Effective date: 20131104

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 401120 YUBEI, CHONGQING TO: 211122 NANJING, JIANGSU PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20131104

Address after: Jiangning District of Nanjing City, Jiangsu province 211122 Science Park Road No. 5 dry

Patentee after: Nanjing Frontier Biotechnology Co.,Ltd.

Address before: 401120 Chongqing city Yubei District back street four Xingke Road No. 149 Metro villa 13 buildings 1-9

Patentee before: Chongqing Sheng Sheng Hongkun Enterprise Management Consulting Co.,Ltd.

C56 Change in the name or address of the patentee
CP03 Change of name, title or address

Address after: Jiangning District of Nanjing City, Jiangsu province 211122 Science Park Road No. 5 Building No. 7 dry (Zijin Mountain)

Patentee after: Frontier biopharmaceutical (Nanjing) Limited by Share Ltd.

Address before: Jiangning District of Nanjing City, Jiangsu province 211122 Science Park Road No. 5 dry

Patentee before: Nanjing Frontier Biotechnology Co.,Ltd.

CX01 Expiry of patent term

Granted publication date: 20070725

CX01 Expiry of patent term